source
- FDA staff flag no major concerns for Grail's multi-cancer test ahead of advisory committeeFDA staff have completed a review of Grail's multi-cancer early detection test and reported no major concerns. The assessment comes as the test approaches a scheduled advisory committee meeting, w…
- Cue Biopharma's chronic hives drug clears Phase 2 trial, first immunology data after cancer pivotCue Biopharma announced that its candidate for chronic spontaneous urticaria successfully completed a Phase 2 trial in China. The trial marks the company's first clinical data since it shifted its…Endpoints · 1mo agoPositive readoutPositive